Urge your members of Congress to support continued medical research funding
While exercise offers benefits for a wide range of health conditions, it has historically been considered too dangerous for people living with sickle cell disease (SCD). However, a new study published today in the journal Blood adds to mounting evidence that low-to moderate-intensity exercise may be not only safe, but beneficial for these patients.
Older adults with blood cancers can benefit from a team-based, holistic evaluation before undergoing transplantation, according to a new study published today in Blood Advances. The study, which reported on a multidisciplinary clinic (MDC) at the University of Chicago Medical Center, found that patients treated with this approach experienced better transplantation outcomes and survival rates.
ASH is pleased to recognize the following trainees, who’s meritorious scientific abstract has received one of the awards in the ASH Abstract Achievement Award program portfolio, at the 61st ASH Annual Meeting, December 7-10 in Orlando.
A survey of U.S. hematology-oncology fellows suggests medical school plays an important role in shaping their interest in pursuing careers in hematology, particularly when students are exposed to hematology and oncology as part of core clerkships in internal medicine and pediatrics.
The American Society of Hematology today announced the election of three new members to its Executive Committee for terms beginning after the 2019 ASH Annual Meeting, December 7-10 in Orlando.
ASH will recognize Stanley Schrier, MD, a past ASH president and formerly Professor Emeritus of Medicine in Hematology at Stanford School of Medicine in Stanford, California, with the 2019 Exemplary Service Award for his exceptional years of service and dedication to ASH and to hematology.
Among patients with multiple myeloma, African Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances. The study found that on average it took about three months for white patients to start novel therapy after diagnosis, while for both African Americans and Hispanics it took about five months.
Yesterday, ASH President Roy Silverstein, MD, of the Medical College of Wisconsin asked members of the United States Senate Committee on Appropriations to adopt the provision in the House-passed fiscal year (FY) 2020 Labor, Health and Human Services, Education, and Related Agencies appropriations bill that dedicates $2 million for a federal program to collect data on the complications, treatments, and health outcomes of people with sickle cell disease (SCD).
Over half of people prescribed the targeted blood cancer-fighting drug ibrutinib developed new or worsened high blood pressure within six months of starting the medication, according to a new study published online today in Blood.
ASH has announced the names of 19 investigators who have each been awarded $150,000 through the ASH Bridge Grant Program in 2019.
Urge your members of Congress to support continued medical research funding.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology